Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]
- PMID: 30360899
- PMCID: PMC6321790
- DOI: 10.1016/j.ygyno.2018.10.022
Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]
Conflict of interest statement
The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below:
Dr.Wenham reports being a research fund recipient, consultant, advisor, steering committee or DSMB member, or speaker for Tesaro, Clovis, Genentech, Merck, Ovation Diagnostics, Janseen, Mersana, and Tapimmune.
The authors would like to apologise for any inconvenience caused.
Erratum for
-
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.Gynecol Oncol. 2018 Oct;151(1):18-23. doi: 10.1016/j.ygyno.2018.07.021. Epub 2018 Aug 19. Gynecol Oncol. 2018. PMID: 30135020 Free PMC article. Clinical Trial.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
